EBITDA at other companies
Other financials
Where this comes from
Calculated from Mineralys Therapeutics, Inc.’s reported figures.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s EBITDA?
- Mineralys Therapeutics, Inc. (MLYS) reported EBITDA of -$45.33M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s EBITDA changed year-over-year?
- Mineralys Therapeutics, Inc.'s EBITDA decreased by 2.0% year-over-year, from -$44.43M to -$45.33M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s EBITDA?
- Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s EBITDA has grown at a 41.9% compound annual growth rate (CAGR), from -$84.66M to -$170.55M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.